Arcus Biosciences (RCUS) EBIT Margin (2017 - 2026)
Arcus Biosciences (RCUS) posted quarterly EBIT Margin of 788.24% for Q1 2026, down 35252.0% year-over-year from N/an in Q1 2025, and down 128.17% quarter-over-quarter from 345.45% in Q4 2025.
Powered by 
Analysis
Arcus Biosciences (RCUS) EBIT Margin (2017 - 2026) Analysis & Trends
Arcus Biosciences' EBIT Margin history runs 10 years deep, the most recent figure standing at 788.24% for Q1 2026.
- In Q1 2026, EBIT Margin fell 35252.0% year-over-year to 788.24%; the TTM figure through Mar 2026 stood at 168.64% (up 14058.0% YoY), while the FY2025 annual figure was 156.28%, down 2837.0% from the prior year.
- EBIT Margin for Q1 2026 stood at 788.24%, down from 345.45% in the prior quarter.
- The five-year high for EBIT Margin was 5.0% in Q2 2025, with the low at 788.24% in Q1 2026.
- The 5-year median for EBIT Margin is 286.21% (2023), against an average of 329.77%.
- The sharpest annual moves came in 2022 and 2023: EBIT Margin surged 61375 bps in 2022, then plunged 43235 bps in 2023.
- Arcus Biosciences' EBIT Margin stood at 217.65% in 2022, then sank by 199 bps to 650.0% in 2023, then jumped by 39 bps to 396.15% in 2024, then gained by 13 bps to 345.45% in 2025, then slumped by 128 bps to 788.24% in 2026.
- Business Quant data shows RCUS's EBIT Margin at 788.24% in Q1 2026, 345.45% in Q4 2025, and 546.15% in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBIT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.27 Bn | 131.42 Bn | 2.84 Bn | 37.40% |
| 2 | Regeneron Pharmaceuticals | 85.55 Bn | 77.56 Bn | 3.93 Bn | 30.15% |
| 3 | Argenx Se | 63.45 Bn | 58.27 Bn | 1.37 Bn | 32.54% |
| 4 | Moderna | 57.73 Bn | 52.59 Bn | 52.00 Mn | -562.07% |
| 5 | Revolution Medicines | 44.08 Bn | 44.08 Bn | - | - |
| 6 | BeOne Medicines | 39.95 Bn | 34.85 Bn | 1.53 Bn | 19.06% |
| 7 | Alnylam Pharmaceuticals | 35.14 Bn | 31.84 Bn | 992.69 Mn | 17.93% |
| 8 | Royalty Pharma | 28.44 Bn | 27.60 Bn | - | 19.75% |
| 9 | Insmed | 27.32 Bn | 26.16 Bn | 358.27 Mn | -0.36% |
| 10 | Arcus Biosciences | 3.74 Bn | 3.04 Bn | - | -234.15% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -234.15% |
| Mar 31, 2026 | -788.24% |
| Dec 31, 2025 | -345.45% |
| Sep 30, 2025 | -546.15% |
| Jun 30, 2025 | -5.00% |
| Mar 31, 2025 | -435.71% |
| Dec 31, 2024 | -396.15% |
| Sep 30, 2024 | -218.75% |
| Jun 30, 2024 | -271.79% |
| Mar 31, 2024 | -11.03% |
| Dec 31, 2023 | -650.00% |
| Sep 30, 2023 | -250.00% |
| Jun 30, 2023 | -286.21% |
| Mar 31, 2023 | -344.00% |
| Dec 31, 2022 | -217.65% |
| Sep 30, 2022 | -212.12% |
| Jun 30, 2022 | -255.56% |
| Mar 31, 2022 | -372.22% |
| Dec 31, 2021 | 79.25% |
| Sep 30, 2021 | -825.87% |